HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antibiotics for preterm rupture of membranes.

AbstractBACKGROUND:
Premature birth carries substantial neonatal morbidity and mortality. Subclinical infection is associated with preterm rupture of membranes (PROM). Prophylactic maternal antibiotic therapy might lessen infectious morbidity and delay labour, but could suppress labour without treating underlying infection.
OBJECTIVES:
To evaluate the immediate and long-term effects of administering antibiotics to women with PROM before 37 weeks, on maternal infectious morbidity, neonatal morbidity and mortality, and longer-term childhood development.
SEARCH METHODS:
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 September 2013).
SELECTION CRITERIA:
Randomised controlled trials comparing antibiotic administration with placebo that reported clinically relevant outcomes were included as were trials of different antibiotics. Trials in which no placebo was used were included for the outcome of perinatal death alone.
DATA COLLECTION AND ANALYSIS:
We extracted data from each report without blinding of either the results or the treatments that women received. We sought unpublished data from a number of authors.
MAIN RESULTS:
We included 22 trials, involving 6872 women and babies.The use of antibiotics following PROM is associated with statistically significant reductions in chorioamnionitis (average risk ratio (RR) 0.66, 95% confidence interval (CI) 0.46 to 0.96, and a reduction in the numbers of babies born within 48 hours (average RR 0.71, 95% CI 0.58 to 0.87) and seven days of randomisation (average RR 0.79, 95% CI 0.71 to 0.89). The following markers of neonatal morbidity were reduced: neonatal infection (RR 0.67, 95% CI 0.52 to 0.85), use of surfactant (RR 0.83, 95% CI 0.72 to 0.96), oxygen therapy (RR 0.88, 95% CI 0.81 to 0.96), and abnormal cerebral ultrasound scan prior to discharge from hospital (RR 0.81, 95% CI 0.68 to 0.98). Co-amoxiclav was associated with an increased risk of neonatal necrotising enterocolitis (RR 4.72, 95% CI 1.57 to 14.23).One study evaluated the children's health at seven years of age (ORACLE Children Study) and found antibiotics seemed to have little effect on the health of children.
AUTHORS' CONCLUSIONS:
Routine prescription of antibiotics for women with preterm rupture of the membranes is associated with prolongation of pregnancy and improvements in a number of short-term neonatal morbidities, but no significant reduction in perinatal mortality. Despite lack of evidence of longer-term benefit in childhood, the advantages on short-term morbidities are such that we would recommend antibiotics are routinely prescribed. The antibiotic of choice is not clear but co-amoxiclav should be avoided in women due to increased risk of neonatal necrotising enterocolitis.
AuthorsSara Kenyon, Michel Boulvain, James P Neilson
JournalThe Cochrane database of systematic reviews (Cochrane Database Syst Rev) Issue 12 Pg. CD001058 (Dec 02 2013) ISSN: 1469-493X [Electronic] England
PMID24297389 (Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
Chemical References
  • Anti-Bacterial Agents
  • Macrolides
  • Amoxicillin-Potassium Clavulanate Combination
Topics
  • Amoxicillin-Potassium Clavulanate Combination (adverse effects)
  • Anti-Bacterial Agents (adverse effects, therapeutic use)
  • Child
  • Chorioamnionitis (prevention & control)
  • Developmental Disabilities (prevention & control)
  • Female
  • Fetal Membranes, Premature Rupture (drug therapy)
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Length of Stay
  • Macrolides (therapeutic use)
  • Perinatal Mortality
  • Pregnancy
  • Pregnancy Complications, Infectious (mortality, prevention & control)
  • Premature Birth (prevention & control)
  • Randomized Controlled Trials as Topic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: